Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D
Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D
复制标题
IBS 患者血清连蛋白升高，且与 IBS-D 患者大便频率相关
DOI：
10.1177/2050640619826419
复制
发表时间：
2019-06-01
影响因子：
6
通讯作者：
Lembo, Anthony
中科院分区：
文献类型：
--
作者：
Singh, Prashant;Silvester, Jocelyn;Lembo, Anthony
背景研究表明肠易激综合征患者的肠道通透性增加。验证肠易激综合征患者肠道通透性改变的血清生物标志物将有助于研究和基于病理生理学的治疗。目的检测腹泻型肠易激综合征和便秘型肠易激综合征患者血清带状蛋白和肠道脂肪酸结合蛋白水平，并与健康对照组和乳糜泻患者进行比较。方法采用双抗体夹心酶联免疫吸附试验检测50例便秘型肠易激综合征、50例腹泻型肠易激综合征、53例乳糜泻患者和42例健康体检者的血清带状蛋白和肠道脂肪酸结合蛋白水平。使用肠易激综合征症状严重程度量表测量肠易激综合征症状严重程度。结果便秘型肠易激综合征和腹泻型肠易激综合征患者血清zonin水平明显高于健康对照组(p分别为0.006和0.009)，与活动期乳糜泻患者比较差异无统计学意义。虽然带状蛋白水平与肠易激综合征症状严重程度评分不相关，但与腹泻型肠易激综合征患者每周排便次数(p=0.03)和对排便习惯的不满意(p=0.007)呈正相关。腹泻型肠易激综合征和便秘型肠易激综合征患者的肠道脂肪酸结合蛋白水平均低于腹泻型肠易激综合征患者(p=0.005和p=0.047)。结论肠易激综合征患者血清带状蛋白水平升高，与肠易激综合征患者血清带状蛋白水平相当。在腹泻型肠易激综合征患者中，Zonlin水平与排便习惯的严重程度相关。肠易激综合征患者的肠道脂肪酸结合蛋白水平没有增加，这表明肠细胞死亡没有显着增加。
Background Studies have shown increased intestinal permeability in irritable bowel syndrome. Validating serum biomarkers for altered intestinal permeability in irritable bowel syndrome will facilitate research and pathophysiology-based therapy. Objective To measure serum zonulin and intestinal fatty acid binding protein levels in diarrhea-predominant irritable bowel syndrome and constipation-predominant irritable bowel syndrome and compare with healthy controls and celiac disease. Methods Serum zonulin and intestinal fatty acid binding protein levels were measured using enzyme-linked immunosorbent assays in constipation-predominant irritable bowel syndrome (n = 50), diarrhea-predominant irritable bowel syndrome (n = 50), celiac disease (n = 53) and healthy controls (n = 42). Irritable bowel syndrome symptom severity was measured using the irritable bowel syndrome-symptom severity scale. Results Patients with constipation-predominant irritable bowel syndrome and diarrhea-predominant irritable bowel syndrome had higher zonulin levels compared with healthy controls (p = 0.006 and 0.009 respectively), which was comparable to those with active celiac disease. Although zonulin levels did not correlate with the overall irritable bowel syndrome symptom severity scale, it positively correlated with stool frequency per week (p = 0.03) and dissatisfaction with bowel habits (p = 0.007) in diarrhea-predominant irritable bowel syndrome. Patients with diarrhea-predominant irritable bowel syndrome and constipation-predominant irritable bowel syndrome had lower intestinal fatty acid binding protein levels compared with celiac patients (p = 0.005 and p = 0.047 respectively). Conclusion Serum zonulin is upregulated in irritable bowel syndrome and the levels are comparable to those in celiac disease. Zonulin levels correlated with severity of bowel habits in diarrhea-predominant irritable bowel syndrome. Intestinal fatty acid binding protein levels in irritable bowel syndrome patients were not increased suggesting no significant increase in enterocyte death.